Press Releases
Media
Publications

April 5, 2025

Decoy-resistant IL-18 for relapse or preemptive treatment of MRD+ AML and MDS after allogeneic HSCT

DAVA Oncology’s 12th Whistler Summit on Hematological Malignancies
Jacob Applebaum

December 9, 2024

Preclinical efficacy of decoy-resistant IL-18 in hematological malignancies

Poster Presentation at ASH Annual Meeting 2024
Jeffrey N. Lindquist, Kai Qin, Jeffrey M. Liu, Aaron M. Ring, Hirdesh Uppal

December 9, 2024

Trials in Progress: Decoy-Resistant Interleukin-18 (DR-18) for Relapse or Pre-Emptive Treatment of Measurable Residual Disease after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome (DR. DREAM), a Phase I Trial

Poster Presentation at ASH Annual Meeting 2024
Elizabeth Krakow, Laura Connelly-Smith, Catherine J. Lee, Dow Dunbar, Jeremy Barton, Beatrice P. McQueen, Geoffrey R. Hill and Jacob S. Appelbaum

November 19, 2024

Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma

JCI Insight 10: 1
David A. Schoenfeld, Dijana Djureinovic, David G. Su, Lin Zhang, Benjamin Y. Lu, Larisa Kamga, Jacqueline E. Mann, John D. Huck, Michael Hurwitz, David A. Braun, Lucia Jilaveanu, Aaron M. Ring and Harriet M. Kluger

November 5, 2024

Trial in Progress: ST-067 (decoy-resistant IL-18) with teclistamab in multiple myeloma

Online-only Abstract from ASH Annual Meeting 2024
Rahul Banerjee, Jacquelin Vandermeer, Jeremy Barton, Michael Mangone, Beatrice P. McQueen, Jordan Gauthier, Aaron M Ring, Ajay K. Gopal, Geoffrey R. Hill and Andrew J. Cowan

April 9, 2024

Decoy-resistant IL-18 enhances checkpoint inhibitor combinations beyond anti-PD-1 in vitro and in vivo

Poster Presentation at AACR Annual Meeting 2024
Jeffrey N. Lindquist, Kai Qin, Aaron M. Ring and Hirdesh Uppal

November 4, 2023

A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies

Poster Presentation at SITC Annual Meeting 2023
Justin C. Moser, Ryan Sullivan, Matthew H. Taylor, Igor Puzanov, Gerald S. Falchook, Mario Sznol, Virginia E. Paton, David Chonzi, Brage Garofalo, Mark Sonnemann, Hirdesh Uppal, Jeremy Barton, Beatrice Y. McQueen, Aaron M. Ring and Harriet Kluger

October 25, 2023

Developing synthetic tools to decipher the tumor-immune interactome

PNAS 120: 44
Orr-El Wiezman, Sophia Luyten, Peiwen Lu, Eric Song, Kai Qin, Darium Mostaghimi, Aaron M. Ring and Akiko Iwasaki

October 25, 2022

Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity

Science Immunology 7: 76
Simone A. Minnie, Olivia G. Waltner, Kathleen S. Ensbey, Nicole S. Nemychenkov, Christine R. Schmidt, Shruti S. Bhise, Samuel R. W. Legg, Gabriela Campoy, Luke D. Samson, Rachel D. Kuns, Ting Zhou, John D. Huck, Slavica Vuckovic, Danniel Zamora, Albert Yeh, Andrew Spencer, Motoko Koyama, Kate A. Markey, Steven W. Lane, Michael Boeckh, Aaron M. Ring, Scott N. Furlan, Geoffrey R. Hill

June 24, 2020

IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy

Nature 583, 609–614
Ting Zhou, William Damsky, Orr-El Weizman, Meaghan K. McGeary, K. Patricia Hartmann, Connor E. Rosen, Suzanne Fischer, Ruaidhri Jackson, Richard A. Flavell, Jun Wang, Miguel F. Sanmamed, Marcus W. Bosenberg & Aaron M. Ring

December 5, 2024

Simcha Therapeutics Announces the Opening of Two Clinical Studies Exploring ST-067 in Hematological Indications

January 8, 2024

Simcha Therapeutics Announces License & Option Agreement to Develop Novel Decoy-resistant IL-18 for Use in Cell Therapy Applications

August 22, 2023

Simcha Therapeutics Announces its Scientific Advisory Board, Comprised of Renowned Experts in Immunology and Oncology

July 6, 2023

Simcha Therapeutics Announces First Patient Dosed in Phase 1/2 Study Evaluating ST-067 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Various Solid Tumors

April 5, 2023

Simcha Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ST-067 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Various Solid Tumors

August 16, 2022

Simcha Therapeutics Accelerates Growth with Key Leadership Appointments, Expanded Research and Option Agreement with Yale School of Medicine

January 27, 2022

Simcha Therapeutics Raises $40 Million Series B Financing and Initiates Phase 1/2 Study to Evaluate Novel Interleukin-18 Variant in Cancer

June 24, 2020

Simcha Therapeutics Launches to Engineer Therapeutic Cytokines to Unlock the Full Potential of the Immune System

February 1, 2024

Growing IL-18 field looks to enhance cell therapies via decoy evasion

June 14, 2023

Immunotherapies for Cancer and More: Aaron Ring on The Long Run

December 8, 2022

Enlisting Next-Generation Cytokine Immunotherapies in the Fight Against Cancer

December 7, 2022

ASH22 could be IL-18’s watershed moment

January 27, 2022

Going after an old GSK target in a new way, a Yale spinout hits the clinic and nabs a modest raise

June 24, 2020

Engineering a better immunotherapy to outwit cancer — and launch a biotech

June 24, 2020

Simcha debuts with $25M to advance custom-built IL-18 for cancer